Evidence map›Paper›PMID 25586140›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2015

Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo.

Gesthimani Samiotaki, Camilo Acosta, Shutao Wang, Elisa E Konofagou

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Cavitation-modulated inflammatory response following focused ultrasound blood-brain barrier opening.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. A High-Frequency Phased Array System for Transcranial Ultrasound Delivery in Small Animals.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2021
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Gesthimani SamiotakiDepartment of Biomedical Engineering, Columbia University, New York, New York, USA.
Camilo AcostaDepartment of Biomedical Engineering, Columbia University, New York, New York, USA.
Shutao WangDepartment of Radiology, Columbia University, New York, New York, USA.
Elisa E Konofagou1] Department of Biomedical Engineering, Columbia University, New York, New York, USA [2] Department of Radiology, Columbia University, New York, New York, USA.
Columbia University · US

Funding

Assessment of Ultrsound-facilitated Neurotherapeutics in Alzheimer's DiseaseR01AG038961 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI KONOFAGOU, ELISA E. · 2011 to 2020
$5.1M
Optimization of ultrasound-facilitated blood-brain barrier openingR01EB009041 · NIBIB · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI KONOFAGOU, ELISA E. · 2008 to 2017
$4.4M
NIA NIH HHS R01 AG038961NIBIB NIH HHS R01 EB009041
6 · The paper itself

Abstract

The blood-brain barrier (BBB) constitutes a major obstacle in brain drug delivery. Focused ultrasound (FUS) in conjunction with microbubbles has been shown to open the BBB noninvasively, locally, and transiently to allow large molecules diffusion. Neurturin (NTN), a member of the glial-derived neurotrophic factor (GDNF) family, has been demonstrated to have neuroprotective and regenerative effects on dopaminergic neurons in vivo using invasive drug delivery methods. The brain's ascending nigrostriatal pathway is severely damaged in Parkinson's disease (PD), and therefore the substantia nigra (SN) and striatal caudoputamen (CP) were selected as the target areas. The objective of the study was to investigate whether safe and efficient NTN delivery can be achieved through FUS-induced BBB opening via intravenous administration, and thus trigger the neuroregeneration cascade in the nigrostriatal pathway. After the optimization of FUS parameters and target locations in the murine brain, NTN bioavailability and downstream signaling were detected and characterized through immunostaining. FUS significantly enhanced the delivery of NTN compared with the direct injection technique, whereas triggering of the signaling cascade was detected downstream to the neuronal nuclei. These findings thus indicate the potential of the FUS method to mediate transport of proteins through the blood-brain barrier in a PD animal model.

Indexed as

AnimalsBlood-Brain BarrierCorpus StriatumDrug Delivery SystemsEquipment DesignMaleMiceMice, Inbred C57BLNeuroprotective AgentsNeurturinParkinson DiseaseRats, Sprague-DawleySignal TransductionSonicationNeuroprotective AgentsNeurturin

Identifiers

PMID25586140
PMCPMC4420879
OpenAlexW2109794373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.